1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU Anti-Competition Crackdown Boosts Access To Affordable Drugs, Commission Finds

 
• By Eliza Slawther

A report from the European Commission highlights how the enforcement of pharmaceutical antitrust rules between 2018 and 2022 increased the availability of fairly priced innovative medicines in the bloc.

Competition Law
• Source: Shutterstock

The European Commission and national competition authorities imposed fines exceeding €780m ($846m) in relation to 26 cases of pharmaceutical product anti-competitive practices between 2018 and 2022, a new report from the commission has revealed.

These sanctions were made for a variety of reasons, including the misuse of the EU drug patent system to prolong market exclusivity, disparagement of a competitor's products to protect the dominant company's sales,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.